Paffenholz P, et al. - Authors sought to identify potential risk factors for the development of venous thromboembolic events in testicular cancer patients receiving platinum-based chemotherapy. A retrospective analysis was performed including 255 patients with testicular germ cell tumors who received platinum-based chemotherapy from 2003 to 2018 as a multi-center observational cohort study. A venous thromboembolic event, associated with reduced overall survival, was seen in 19% of all patients treated by platinum-based chemotherapy due to testicular cancer. Therefore the main goal of the treating physicians should be monitoring of cancer patients at risk as well as the improvement of patients’ awareness of a thromboembolic event.